Prognostic Value of TARC and Quantitative PET Parameters in Relapsed/Refractory Hodgkin Lymphoma Treated With Brentuximab Vedotin and DHAP
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
Leukemia 2022 Oct 14;[EPub Ahead of Print], J Driessen, MJ Kersten, L Visser, A van den Berg, SH Tonino, JM Zijlstra, PJ Lugtenburg, F Morschhauser, M Hutchings, S Amorim, T Gastinne, M Nijland, GJC Zwezerijnen, R Boellaard, HCW de Vet, AIJ Arens, R Valkema, RDK Liu, EEE Drees, D de Jong, WJ Plattel, A DiepstraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.